Core Points - The National Healthcare Security Administration (NHSA) introduced measures to support the high-quality development of innovative drugs, emphasizing the encouragement of innovative drug exports and the establishment of global trading platforms for innovative drugs [1][3][6] - The number of approved innovative drugs in China has significantly increased, with projections indicating 48 new approvals in 2024, which is over five times the number in 2018 [3] - The introduction of a commercial health insurance innovative drug directory aims to adapt to the multi-tiered medical security system, focusing on high-innovation drugs that exceed basic insurance coverage [4][5] Group 1: Support for Innovative Drug Development - The NHSA's measures include 16 initiatives across five areas: enhancing support for innovative drug research, integrating innovative drugs into insurance directories, encouraging clinical applications, improving payment capabilities, and strengthening organizational support [3][4] - The commercial health insurance innovative drug directory will allow companies to apply for inclusion in both the insurance and commercial directories, with significant decision-making power given to insurance experts [4][5] Group 2: International Expansion of Chinese Innovative Drugs - The measures aim to facilitate the global market development of Chinese innovative drugs, including building trading platforms and providing price support [7] - Hong Kong is positioned as a key hub for the export of innovative drugs, with plans for a new drug registration mechanism to be implemented by the end of 2026 [8][9] - The "1+" approval mechanism in Hong Kong allows for expedited registration of innovative drugs, which is expected to increase the number of mainland innovative drugs entering the Hong Kong market [9][10] Group 3: Industry Impact and Future Prospects - Industry analysts believe that while the impact of these policies may take time to materialize, the overall direction is positive for the pharmaceutical sector [5] - The collaboration between mainland China and Hong Kong is seen as a significant step towards enhancing the international presence of Chinese innovative drugs [10][12]
国家医保局支持创新药出海 企业未来如何借助港澳优势走向全球？